Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations by Westerink, Lotte, Nicolai, Jelmer L. J., Samuelsen, Carl, Smit, Hans J. M., Postmus, Pieter E., Griebsch, Ingolf, Postma, Maarten J.

Get full text

Trends in NICE technology appraisals of non-small cell lung cancer drugs over the last decade by Westerink, Lotte, Wolters, Sharon, Zhou, Guiling, Postma, Arjan, Boersma, Cornelis, van Boven, Job Frank Martien, Postma, Maarten Jacobus

Get full text

Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) by Westerink, Lotte, Nicolai, Jelmer Lennart Jens, Postma, Maarten Jacobus, van Boven, Job Frank Martien, Boersma, Cornelis

Get full text

Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population by Kaasenbrood, Lotte, Boekholdt, S Matthijs, van der Graaf, Yolanda, Ray, Kausik K, Peters, Ron J.G, Kastelein, John J.P, Amarenco, Pierre, LaRosa, John C, Cramer, Maarten J.M, Westerink, Jan, Kappelle, L Jaap, de Borst, Gert J, Visseren, Frank L.J

Get full text